RxDoctor Payments Data

Mindy Rabinowitz, MD

Otolaryngology · Wilmington, DENPI 1962727701

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (54.2%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Medtronic at 53.9% of the total. Reporting peaked in 2022 at $805 and has fallen 59.5% since, to $326 in 2025.

$2,706in general payments, 2019–2025

Across 20 payments — averaging $135.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Integra Lifesciences Corporation$426
  • Stryker$380
  • Regeneron$140
  • Sanofi$133
  • Acclarent, Inc$84
  • plus $85 from 3 others

What the payments were for

  • Consulting fees$84031%
  • Speaking & faculty fees$40015%
  • Food & beverage$1,46654%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,706 in reported general payments places this provider in the 70th percentile of 27 otolaryngology providers in Delaware.

See all otolaryngology providers in Delaware

Medicare billing

Part B allowed, 2024
$144,291
Medicare patients
222
Services billed
1,165

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab20$75,243
Dupixent SyringeDupilumab12$44,571
Ipratropium Bromide157$4,466
Mometasone Furoate51$3,851
Azelastine Hcl87$1,508
Fluticasone Propionate111$1,437
Olopatadine Hcl14$1,112
Montelukast Sodium61$756
Levocetirizine Dihydrochloride26$535
Mupirocin41$429
Minocycline Hcl35$276
Methylprednisolone38$194
Doxycycline Monohydrate12$93
Ciprofloxacin Hcl21$75
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav12$70

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →